Increased CD33 expression associates with increased AD susceptibility, whereas expression of CD33 lacking a sialic acid–binding domain reduces risk (3, 15), implicating CD33-mediated limitation of amyloid clearance as the mechanism for enhanced AD susceptibility. The gene discussed is CD33; the disease is Alzheimer disease.